<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412164</url>
  </required_header>
  <id_info>
    <org_study_id>TARGET II</org_study_id>
    <nct_id>NCT01412164</nct_id>
  </id_info>
  <brief_title>Observational Registry Study: FIREHAWK DES for Treating Coronary Artery Disease (CAD)</brief_title>
  <official_title>A Prospective Multicenter Single-Arm Observational Registry Study Assessing the Safety and Efficacy of FIREHAWK Biodegradable Polymer Target-release Rapamycin-eluting Stent for the Treatment of Coronary Artery Disease: TARGET II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai MicroPort Medical (Group) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai MicroPort Medical (Group) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to further assess the safety, efficacy and the performance of its delivery
      system of FIREHAWK rapamycin-eluting stent up to five years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective open-labeled, multi-center, single-arm observational registry study.
      Approximately 1,100 subjects will be enrolled to evaluate the TLF as the primary endpoint at
      12-month. Also, the study will follow up those subjects up to 5 years as the secondary
      endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TLF (Target Lesion Failure) Rate</measure>
    <time_frame>12 months after index procedure</time_frame>
    <description>Percentage of participants with determination of TLF ,TLF is the composite of cardiac death, target vessel MI and clinically driven TLR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent Implantation Success Rate (SIS Rate)</measure>
    <time_frame>immediately after the procedure</time_frame>
    <description>Stent implantation success (SIS) means participant successfully implanted stent, defined as residual stenosis of the lesion less than 30% and TIMI bloodflow Grade III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-related Cardiovascular Clinical Composite Endpoints</measure>
    <time_frame>1 years after index PCI</time_frame>
    <description>Participants with cardiovascular clinical composite endpoints. Cardiovascular clinical composite endpoints defined as the composite of all death, all MI and vascular reconstruction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-related Cardiovascular Clinical Composite Endpoints</measure>
    <time_frame>3 years after index PCI</time_frame>
    <description>Participants with cardiovascular clinical composite endpoints. Cardiovascular clinical composite endpoints defined as the composite of all death, all MI and vascular reconstruction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-related Cardiovascular Clinical Composite Endpoints</measure>
    <time_frame>5 years after index PCI</time_frame>
    <description>Participants with cardiovascular clinical composite endpoints. Cardiovascular clinical composite endpoints defined as the composite of all death, all MI and vascular reconstruction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF (Target Lesion Failure)</measure>
    <time_frame>1 years after index PCI</time_frame>
    <description>Percentage of participants with determination of TLF ,TLF is the composite of cardiac death, target vessel MI and clinically driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF (Target Lesion Failure)</measure>
    <time_frame>3 years after index PCI</time_frame>
    <description>Participants with the determination of TLF, TLF is the composite of cardiac death, target vessel MI and clinically driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF (Target Lesion Failure)</measure>
    <time_frame>5 years after index PCI</time_frame>
    <description>Participants with the determination of TLF. TLF is the composite of cardiac death, target vessel MI and clinically driven TLR at 12 months post procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">730</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Firehawk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FIREHAWK biodegradable polymer rapamycin-eluting stent</intervention_name>
    <description>DES PCI for CAD</description>
    <arm_group_label>Firehawk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75, male or unpregnant women

          -  Evidence of non-symptomatic ischemia, stable or non-stable angina or past MI

          -  Native coronary artery target lesion

          -  Target lesion length &lt;=60mm, target lesion vessel diameter 2.25mm-4.0mm

          -  Target lesion diameter stenosis&gt;=70%

          -  For each target lesion, Firehawk stent implantation only

          -  Understand the study purpose, willing to participate and sign the letter of consent

          -  Acceptance of clinical follow-up

        Exclusion Criteria:

          -  Acute MI within 72 hours

          -  Unprotected LM and intervention-required three-vessel lesions

          -  Calcified lesion failed in pre-dilation and twisted lesion

          -  Bridge vessel lesion

          -  Any stent implanted within one year

          -  Severe heart failure (HYHA&gt;=III) or LVEF&lt;40%

          -  Renal deficiency, blood creatinine &gt; 2.0mg/dl

          -  Bleeding tendency

          -  Allergic to aspirin, clopidogrel, ticlopidine, dye, rapamycin and metal

          -  Life expectation &lt;12 months

          -  History of not achieving study finish

          -  No compliances to the protocol

          -  Heart implantation subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runlin Gao, M.D., Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fu Wai Hospital, Beijing, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <results_first_submitted>February 19, 2016</results_first_submitted>
  <results_first_submitted_qc>February 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2016</results_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DES</keyword>
  <keyword>CAD</keyword>
  <keyword>FIREHAWK</keyword>
  <keyword>MicroPort</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Firehawk</title>
          <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
FIREHAWK biodegradable polymer rapamycin-eluting stent: DES PCI for CAD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="730"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="683"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Firehawk</title>
          <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
FIREHAWK biodegradable polymer rapamycin-eluting stent: DES PCI for CAD</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="730"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.71" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>TLF (Target Lesion Failure) Rate</title>
        <description>Percentage of participants with determination of TLF ,TLF is the composite of cardiac death, target vessel MI and clinically driven TLR</description>
        <time_frame>12 months after index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Firehawk</title>
            <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
FIREHAWK biodegradable polymer rapamycin-eluting stent: DES PCI for CAD</description>
          </group>
        </group_list>
        <measure>
          <title>TLF (Target Lesion Failure) Rate</title>
          <description>Percentage of participants with determination of TLF ,TLF is the composite of cardiac death, target vessel MI and clinically driven TLR</description>
          <units>percentage of participants with TLF</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="730"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Implantation Success Rate (SIS Rate)</title>
        <description>Stent implantation success (SIS) means participant successfully implanted stent, defined as residual stenosis of the lesion less than 30% and TIMI bloodflow Grade III</description>
        <time_frame>immediately after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Firehawk</title>
            <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
FIREHAWK biodegradable polymer rapamycin-eluting stent: DES PCI for CAD</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Implantation Success Rate (SIS Rate)</title>
          <description>Stent implantation success (SIS) means participant successfully implanted stent, defined as residual stenosis of the lesion less than 30% and TIMI bloodflow Grade III</description>
          <units>percentage of participants with SIS</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="730"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-related Cardiovascular Clinical Composite Endpoints</title>
        <description>Participants with cardiovascular clinical composite endpoints. Cardiovascular clinical composite endpoints defined as the composite of all death, all MI and vascular reconstruction.</description>
        <time_frame>1 years after index PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Firehawk</title>
            <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
FIREHAWK biodegradable polymer rapamycin-eluting stent: DES PCI for CAD</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-related Cardiovascular Clinical Composite Endpoints</title>
          <description>Participants with cardiovascular clinical composite endpoints. Cardiovascular clinical composite endpoints defined as the composite of all death, all MI and vascular reconstruction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="730"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-related Cardiovascular Clinical Composite Endpoints</title>
        <description>Participants with cardiovascular clinical composite endpoints. Cardiovascular clinical composite endpoints defined as the composite of all death, all MI and vascular reconstruction.</description>
        <time_frame>3 years after index PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Firehawk</title>
            <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
FIREHAWK biodegradable polymer rapamycin-eluting stent: DES PCI for CAD</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-related Cardiovascular Clinical Composite Endpoints</title>
          <description>Participants with cardiovascular clinical composite endpoints. Cardiovascular clinical composite endpoints defined as the composite of all death, all MI and vascular reconstruction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-related Cardiovascular Clinical Composite Endpoints</title>
        <description>Participants with cardiovascular clinical composite endpoints. Cardiovascular clinical composite endpoints defined as the composite of all death, all MI and vascular reconstruction.</description>
        <time_frame>5 years after index PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Firehawk</title>
            <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
FIREHAWK biodegradable polymer rapamycin-eluting stent: DES PCI for CAD</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-related Cardiovascular Clinical Composite Endpoints</title>
          <description>Participants with cardiovascular clinical composite endpoints. Cardiovascular clinical composite endpoints defined as the composite of all death, all MI and vascular reconstruction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="683"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TLF (Target Lesion Failure)</title>
        <description>Percentage of participants with determination of TLF ,TLF is the composite of cardiac death, target vessel MI and clinically driven TLR</description>
        <time_frame>1 years after index PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Firehawk</title>
            <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
FIREHAWK biodegradable polymer rapamycin-eluting stent: DES PCI for CAD</description>
          </group>
        </group_list>
        <measure>
          <title>TLF (Target Lesion Failure)</title>
          <description>Percentage of participants with determination of TLF ,TLF is the composite of cardiac death, target vessel MI and clinically driven TLR</description>
          <units>percentage of participants with TLF</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="730"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TLF (Target Lesion Failure)</title>
        <description>Participants with the determination of TLF, TLF is the composite of cardiac death, target vessel MI and clinically driven TLR</description>
        <time_frame>3 years after index PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Firehawk</title>
            <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
FIREHAWK biodegradable polymer rapamycin-eluting stent: DES PCI for CAD</description>
          </group>
        </group_list>
        <measure>
          <title>TLF (Target Lesion Failure)</title>
          <description>Participants with the determination of TLF, TLF is the composite of cardiac death, target vessel MI and clinically driven TLR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TLF (Target Lesion Failure)</title>
        <description>Participants with the determination of TLF. TLF is the composite of cardiac death, target vessel MI and clinically driven TLR at 12 months post procedure</description>
        <time_frame>5 years after index PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Firehawk</title>
            <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
FIREHAWK biodegradable polymer rapamycin-eluting stent: DES PCI for CAD</description>
          </group>
        </group_list>
        <measure>
          <title>TLF (Target Lesion Failure)</title>
          <description>Participants with the determination of TLF. TLF is the composite of cardiac death, target vessel MI and clinically driven TLR at 12 months post procedure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="683"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Firehawk</title>
          <description>Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
FIREHAWK biodegradable polymer rapamycin-eluting stent: DES PCI for CAD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Perioperative myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Target lesion revascularization</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Definite/probable in-stent thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kefei Li</name_or_title>
      <organization>Shanghai Microport Medical (Group) Co.,Ltd.</organization>
      <phone>+86-21-38954600Ã—6700</phone>
      <email>kfli@microport.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

